Publications by authors named "Ingrid Pabinger-Fasching"

10 Publications

  • Page 1 of 1

The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.

Thromb Res 2016 May;141 Suppl 3:S2-4

Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Electronic address:

For patients with hemophilia A, replacement of deficient factor VIII (FVIII) using plasma-derived or recombinant FVIII (rFVIII) products to restore hemostatic control can reduce bleeding complications and preserve musculoskeletal function. Despite the clinical availability of several of these products, challenges remain in the treatment of hemophilia A, the most notable of which are the risk of inhibitor development and the limited half-life of existing FVIII concentrates, which can make prophylaxis burdensome for patients. The use of recombinant protein technology may lead to novel FVIII products with improved properties. This article describes the story of a unique recombinant FVIII protein, rVIII-SingleChain, which is currently in development. In contrast to native FVIII and other commercially available rFVIII preparations, rVIII-SingleChain uses a strong, covalent bond to connect the light and heavy chains, thereby creating a stable, single-chain rFVIII. It has enhanced intrinsic stability, better integrity after reconstitution, and a higher binding affinity to von Willebrand factor. The physicochemical profile of rVIII-SingleChain and preclinical data on its activity and phamacokinetics strengthened the rationale for its clinical investigation. Available data from the AFFINITY clinical trial program are promising; indicating that it has good hemostatic efficacy when used on demand, for prophylaxis, and in the surgical setting, and is also very well tolerated. A pediatric study and an extension study are ongoing as part of the AFFINITY program.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0049-3848(16)30414-5DOI Listing
May 2016

Pioneering therapeutic proteins in hemophilia care through innovative technologies.

Thromb Res 2016 May;141 Suppl 3:S1

Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0049-3848(16)30413-3DOI Listing
May 2016

[Prevention of venous thromboembolism in musculoskeletal surgery].

Wien Klin Wochenschr 2014 May 14;126(9-10):298-310. Epub 2014 May 14.

Klin. Abt. für Hämatologie und Hämostaseologie, Univ.-Klinik für Innere Medizin I, MedUni Wien, Wien, Österreich,

Musculoskeletal surgery is associated with a high risk of venous thrombosis and pulmonary embolism. The introduction of direct oral anticoagulants (DOAK) has broadened the possibilities for prevention of venous thromboembolism in the course of orthopedic and trauma surgery. Addressing this recent development, the Austrian Societies of Orthopedics and Orthopedic Surgery (ÖGO), Trauma Surgery (ÖGU), Hematology and Oncology (OeGHO) and of Anaesthesiology, Reanimation und Intensive Care Medicine (ÖGARI) have taken the initiative to create Austrian guidelines for the prevention of thromboembolism after total hip and knee replacement, hip fracture surgery, interventions at the spine and cases of minor orthopedic and traumatic surgery. Furthermore, the pharmacology of the DOAK and the pivotal trial data for each of the three currently available substances - apixaban, dabigatran, and rivaroxaban - are briefly presented. Separate chapters are dedicated to "anticoagulation and neuroaxial anesthesia" and "bridging".
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-014-0509-5DOI Listing
May 2014

[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].

Wien Klin Wochenschr 2013 Jul;125(13-14):412-20

AKH Wien, Univ.-Klinik für Innere Medizin I, Währinger Gürtel 18–20, 1090 Wien, Österreich.

Interruption of an ongoing therapy with vitamin K antagonists (VKAs) is necessary in almost all patients undergoing major surgery. The purpose of the following expert recommendations is to provide easy to use guidance for the periprocedural management of patients on VKAs based on current evidence from the literature. Management of anticoagulation during the time of interruption of VKAs is based on balancing the thromboembolic (TE) risk of underlying conditions against the bleeding risk of the surgical procedure. VKAs should be stopped 3–7days prior to surgery. Low molecular weight heparin (LMWH) is used to cover (“bridge”) the progressive pre-operative loss of anticoagulation and the slow post-operative onset of anticoagulant activity of VKAs. Patients with high risk of TE should receive a therapeutic dose of LMWH, patients with a moderate risk of TE should receive half of this dose. Patients with a low risk of TE do not need bridging therapy with LMWH. In case of an uneventful postoperative course, patients with a therapeutic pre-operative dose should be treated post-operatively with the same dose, starting on day 4 in case of major surgery and on day 2 in case of minor procedures. Patients with a half-therapeutic preoperative dose should be treated post-operatively with the same dose, starting on day 3 in case of major surgery and on day 1 in case of minor procedures. Therapy with VKAs should be re-instituted on the second post-operative day based on the preoperative dosage. Procedure-related post-operative thromboprophylaxis should be given irrespective of these recommendations on days without “bridging” anticoagulation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-013-0390-7DOI Listing
July 2013

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Blood 2012 Sep 2;120(12):2405-11. Epub 2012 Aug 2.

Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy.

A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate hemophilia B treatment by less frequent FIX dosing. This first-in-human dose-escalation trial in 25 previously treated subjects with hemophilia B (FIX ≤ 2 IU/dL) examined the safety and pharmacokinetics of 25, 50, and 75 IU/kg rIX-FP. Patients in the 50-IU/kg cohort underwent a comparative pharmacokinetics assessment with their previous FIX product (plasma-derived or recombinant). No allergic reactions or inhibitors were observed. Four mild, possibly treatment-related adverse events were reported. In the 50-IU/kg cohort (13 subjects), the mean half-life of rIX-FP was 92 hours, more than 5 times longer than the subjects' previous FIX product. After 25 or 50 IU/kg rIX-FP administration, the baseline-corrected mean FIX activity remained elevated at day 7 (7.4 IU/dL and 13.4 IU/dL, respectively) and day 14 (2.5 IU/dL and 5.5 IU/dL, respectively). The incremental recovery of rIX-FP was higher than both recombinant and plasma-derived FIX (1.4 vs 0.95 and 1.1 IU/dL per IU/kg, respectively). These results demonstrated both the safety and improved pharmacokinetics of rIX-FP, thus indicating this new product with extended half-life as possibly able to control and prevent bleeding with less frequent injection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-05-429688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448255PMC
September 2012

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.

Hematology 2011 Sep;16(5):274-7

CHU Henri Mondor AP-HP, Université Paris, 51 Av du Mal de Lattre de Tassigny, Créteil, France.

Adult patients with primary immune thrombocytopenia requiring first-line treatment typically receive corticosteroids, which are associated with low response rates and many potential side effects. In a retrospective analysis of two 6-month, placebo-controlled, phase III trials, corticosteroid use decreased from 30 to 26% among patients treated with the novel thrombopoietin-mimetic romiplostim (n = 83) and remained above 30% for placebo-treated patients (n = 42). Moreover, compared to placebo, patients were spared 7 weeks of corticosteroid treatment for every 100 weeks of romiplostim treatment. Thereafter, corticosteroid use continued to decrease significantly, from 35 to 20%, in patients treated with romiplostim for up to 3 years in an open-label extension study (n = 101), and patients were spared a further 8 weeks of corticosteroid treatment for each additional 100 weeks of romiplostim treatment. Such reductions in corticosteroids may improve health-related quality of life in patients with primary immune thrombocytopenia.</div><div class="recent-author-more view-article"> <a href="https://www.pubfacts.com/detail/21902890/Reduced-corticosteroid-use-in-adult-patients-with-primary-immune-thrombocytopenia-receiving-romiplos" class="btn btn-default btn-labeled"><span class="btn-label"><i class="icon-book-open"></i></span>View Article and Find Full Text PDF</a> </div><table class="table table-bordered table-striped downloadTable" > <thead > <tr> <th ><h3>Download full-text PDF</h3></th> <th >Source</th> </tr></thead> <tbody><tr><td><i class='icon-doc'></i><a href='http://dx.doi.org/10.1179/102453311X13025568942005' rel='nofollow' target='_blank' onClick='ga("send", "event", "fulltextclick_DOI Listing", "click", "article");' style='text-decoration:underline;' class='clickTrack' data-ref='fulltext-21902890-n' >http://dx.doi.org/10.1179/102453311X13025568942005</a></td><td>DOI Listing</td></tr><tr><td><i class='icon-doc'></i><a href='http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178451' rel='nofollow' target='_blank' onClick='ga("send", "event", "fulltextclick_PMC", "click", "article");' style='text-decoration:underline;' class='clickTrack' data-ref='fulltext-21902890-n'>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178451</a></td><td>PMC</td></tr></tbody></table></div><div class="publication-dtl-rgt fr"><div class="publish-date"> September 2011</div><div class="publication-social"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.pubfacts.com/detail/21902890" target="_blank" title="" class="fb socialShare" id="fb-a-21902890"><i class="icon-facebook"></i></a> <a href="https://twitter.com/intent/tweet?text=Full+Article+on+PubFacts%3A&url=https://www.pubfacts.com/detail/21902890" target="_blank" title="" class="tw socialShare" id="tw-a-21902890"><i class="icon-twitter"></i></a> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://www.pubfacts.com/detail/21902890&title=Reduced+corticosteroid+use+in+adult+patients+with+primary+immune+thrombocytopenia+receiving+romiplostim.&summary=Article+Summary+on+PubFacts.com" target="_blank" title="" class="in socialShare" id="in-a-21902890"><i class="icon-linkedin"></i></a> </div></div> </div> </div><div class="publication-block"><h3><a href="https://www.pubfacts.com/detail/18549908/Warfarin-reversal-results-of-a-phase-III-study-with-pasteurised-nanofiltrated-prothrombin-complex-co" >Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.</a></h3> <div class="publication-auther"> <h5>Authors:</h5> <a href='https://www.pubfacts.com/author/Ingrid+Pabinger-Fasching'>Ingrid Pabinger-Fasching</a> </div> <div class="publication-dtl clearfix"> <div class="publication-dtl-lft fl"><p>Thromb Res 2008 ;122 Suppl 2:S19-22</p><p>Haematology and Haemostaseology Division, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. </p><div class="pubDescriptor" style="margin-top:20px;">Bleeding can be a major problem in patients on oral anticoagulation therapy. Beriplex P/N is a prothrombin complex concentrate (PCC) that has been developed for the rapid reversal of anticoagulation in patients requiring immediate haemostatic control. Beriplex P/N contains high concentrations of the coagulation factors II, VII, IX and X, together with the inhibitors protein C and protein S, and it can be rapidly prepared and administered at an infusion rate of up to 8.0 mL/min. The efficacy of Beriplex P/N in patients requiring emergency reversal of oral anticoagulation has been demonstrated in a prospective, open-label, uncontrolled study involving 43 patients; 17 with acute bleeding and 26 requiring emergency surgery. Beriplex P/N was administered at a dose of 25-50 IU/kg, according to baseline international normalised ratio (INR) in conjunction with vitamin K. Mean INR 30 minutes post-infusion was 1.18, and 93% of patients achieved an INR of <or=1.3. Clinical efficacy was rated as satisfactory or very good in 98% of patients. Therapy was found to be well tolerated. There were no adverse events related to the rapid rate of infusion and, of the 8 serious adverse events reported; only 1 was regarded as being possibly related to treatment. No virus transmission was observed and changes in thrombogenicity markers were found to be transient and did not correspond to any clinically observed thromboembolic events. In conclusion, Beriplex P/N is an effective and well-tolerated therapy for rapid, complete and predictable reversal of anticoagulation in patients with acute bleeding or requiring emergency surgery.</div><div class="recent-author-more view-article"> <a href="https://www.pubfacts.com/detail/18549908/Warfarin-reversal-results-of-a-phase-III-study-with-pasteurised-nanofiltrated-prothrombin-complex-co" class="btn btn-default btn-labeled"><span class="btn-label"><i class="icon-book-open"></i></span>View Article and Find Full Text PDF</a> </div><table class="table table-bordered table-striped downloadTable" > <thead > <tr> <th ><h3>Download full-text PDF</h3></th> <th >Source</th> </tr></thead> <tbody><tr><td><i class='icon-doc'></i><a href='http://dx.doi.org/10.1016/S0049-3848(08)70005-7' rel='nofollow' target='_blank' onClick='ga("send", "event", "fulltextclick_DOI Listing", "click", "article");' style='text-decoration:underline;' class='clickTrack' data-ref='fulltext-18549908-n' >http://dx.doi.org/10.1016/S0049-3848(08)70005-7</a></td><td>DOI Listing</td></tr></tbody></table></div><div class="publication-dtl-rgt fr"><div class="publish-date"> October 2008</div><div class="publication-social"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.pubfacts.com/detail/18549908" target="_blank" title="" class="fb socialShare" id="fb-a-18549908"><i class="icon-facebook"></i></a> <a href="https://twitter.com/intent/tweet?text=Full+Article+on+PubFacts%3A&url=https://www.pubfacts.com/detail/18549908" target="_blank" title="" class="tw socialShare" id="tw-a-18549908"><i class="icon-twitter"></i></a> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://www.pubfacts.com/detail/18549908&title=Warfarin-reversal%3A+results+of+a+phase+III+study+with+pasteurised%2C+nanofiltrated+prothrombin+complex+concentrate.&summary=Article+Summary+on+PubFacts.com" target="_blank" title="" class="in socialShare" id="in-a-18549908"><i class="icon-linkedin"></i></a> </div></div> </div> </div><div class="publication-block"><h3><a href="https://www.pubfacts.com/detail/16129206/The-course-of-anticardiolipin-antibody-levels-under-immunoadsorption-therapy" >The course of anticardiolipin antibody levels under immunoadsorption therapy.</a></h3> <div class="publication-auther"> <h5>Authors:</h5> <a href='https://www.pubfacts.com/author/Anna-Christine+Hauser'>Anna-Christine Hauser</a> <a href='https://www.pubfacts.com/author/Lorenz+Hauser'>Lorenz Hauser</a> <a href='https://www.pubfacts.com/author/Ingrid+Pabinger-Fasching'>Ingrid Pabinger-Fasching</a> <a href='https://www.pubfacts.com/author/Peter+Quehenberger'>Peter Quehenberger</a> <a href='https://www.pubfacts.com/author/Kurt+Derfler'>Kurt Derfler</a> <a href='https://www.pubfacts.com/author/Walter+Hermann+Hörl'>Walter Hermann Hörl</a> </div> <div class="publication-dtl clearfix"> <div class="publication-dtl-lft fl"><p>Am J Kidney Dis 2005 Sep;46(3):446-54</p><p>Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Austria. </p><div class="pubDescriptor" style="margin-top:20px;"><em>Background</em>: The emergence of anticardiolipin antibodies in patients with systemic lupus erythematosus is a serious occurrence in regard to a high risk for thrombosis and thromboembolic complications, fetal loss, and renal insufficiency. In an observational analysis, we studied anticardiolipin antibodies during immunoadsorption therapy.<BR><BR><em>Methods</em>: We analyzed the magnitude and time course of serum concentrations of the immunoglobulin G (IgG) and IgM subtypes of anticardiolipin antibodies (CIgG and CIgM) along with IgG and IgM, antinuclear antibodies, and antibodies to double-stranded DNA before and after single immunoadsorption sessions and their long-term course in 11 patients with systemic lupus erythematosus.<BR><BR><em>Results</em>: Single immunoadsorption sessions (n = 842) led to a rapid decline in CIgG and CIgM levels by 62.94% +/- 21.60% and 42.02% +/- 22.14%, respectively (P < 0.0001), along with a corresponding decline in serum levels of antinuclear antibodies (65.04% +/- 18.83%), antibodies to double-stranded DNA (64.67% +/- 21.20%), IgG (58.11% +/- 16.84%), and IgM (32.15% +/- 15.58%). Reduction rates of CIgG and CIgM levels were greater when high initial concentrations (P < 0.0001) and low IgG levels (P < 0.0001) were present. Mean reductions in pretreatment values of CIgG and CIgM during 6 months of immunoadsorption therapy were 42.85% +/- 39.94% and 29.39% +/- 70.41% (mean number of sessions/patient = 21.55) and for the 1-year period were 63.20% +/- 22.49% and 58.05% +/- 40.16% (mean number of sessions/patient = 30.46).<BR><BR><em>Conclusion</em>: We observed that immunoadsorption therapy is an effective method to reduce anticardiolipin antibody levels rapidly and keep them at a low level in the long term.</div><div class="recent-author-more view-article"> <a href="https://www.pubfacts.com/detail/16129206/The-course-of-anticardiolipin-antibody-levels-under-immunoadsorption-therapy" class="btn btn-default btn-labeled"><span class="btn-label"><i class="icon-book-open"></i></span>View Article and Find Full Text PDF</a> </div><table class="table table-bordered table-striped downloadTable" > <thead > <tr> <th ><h3>Download full-text PDF</h3></th> <th >Source</th> </tr></thead> <tbody><tr><td><i class='icon-doc'></i><a href='http://dx.doi.org/10.1053/j.ajkd.2005.05.023' rel='nofollow' target='_blank' onClick='ga("send", "event", "fulltextclick_DOI Listing", "click", "article");' style='text-decoration:underline;' class='clickTrack' data-ref='fulltext-16129206-n' >http://dx.doi.org/10.1053/j.ajkd.2005.05.023</a></td><td>DOI Listing</td></tr></tbody></table></div><div class="publication-dtl-rgt fr"><div class="publish-date"> September 2005</div><div class="publication-social"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.pubfacts.com/detail/16129206" target="_blank" title="" class="fb socialShare" id="fb-a-16129206"><i class="icon-facebook"></i></a> <a href="https://twitter.com/intent/tweet?text=Full+Article+on+PubFacts%3A&url=https://www.pubfacts.com/detail/16129206" target="_blank" title="" class="tw socialShare" id="tw-a-16129206"><i class="icon-twitter"></i></a> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://www.pubfacts.com/detail/16129206&title=The+course+of+anticardiolipin+antibody+levels+under+immunoadsorption+therapy.&summary=Article+Summary+on+PubFacts.com" target="_blank" title="" class="in socialShare" id="in-a-16129206"><i class="icon-linkedin"></i></a> </div></div> </div> </div><div class="publication-block"><h3><a href="https://www.pubfacts.com/detail/12686684/A-patient-with-sudden-abdominal-pain-10-years-after-successful-renal-transplantation" >A patient with sudden abdominal pain 10 years after successful renal transplantation.</a></h3> <div class="publication-auther"> <h5>Authors:</h5> <a href='https://www.pubfacts.com/author/Anna-Christine+Hauser'>Anna-Christine Hauser</a> <a href='https://www.pubfacts.com/author/Ingrid+Pabinger-Fasching'>Ingrid Pabinger-Fasching</a> <a href='https://www.pubfacts.com/author/Peter+Quehenberger'>Peter Quehenberger</a> <a href='https://www.pubfacts.com/author/Joachim+Kettenbach'>Joachim Kettenbach</a> <a href='https://www.pubfacts.com/author/Walter+H+Hörl'>Walter H Hörl</a> </div> <div class="publication-dtl clearfix"> <div class="publication-dtl-lft fl"><p>Nephrol Dial Transplant 2003 May;18(5):1021-5</p><p>Division of Nephrology, Department of Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. </p><div class="recent-author-more view-article"> <a href="https://www.pubfacts.com/detail/12686684/A-patient-with-sudden-abdominal-pain-10-years-after-successful-renal-transplantation" class="btn btn-default btn-labeled"><span class="btn-label"><i class="icon-book-open"></i></span>View Article and Find Full Text PDF</a> </div><table class="table table-bordered table-striped downloadTable" > <thead > <tr> <th ><h3>Download full-text PDF</h3></th> <th >Source</th> </tr></thead> <tbody><tr><td><i class='icon-doc'></i><a href='http://dx.doi.org/10.1093/ndt/gfg047' rel='nofollow' target='_blank' onClick='ga("send", "event", "fulltextclick_DOI Listing", "click", "article");' style='text-decoration:underline;' class='clickTrack' data-ref='fulltext-12686684-n' >http://dx.doi.org/10.1093/ndt/gfg047</a></td><td>DOI Listing</td></tr></tbody></table></div><div class="publication-dtl-rgt fr"><div class="publish-date"> May 2003</div><div class="publication-social"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.pubfacts.com/detail/12686684" target="_blank" title="" class="fb socialShare" id="fb-a-12686684"><i class="icon-facebook"></i></a> <a href="https://twitter.com/intent/tweet?text=Full+Article+on+PubFacts%3A&url=https://www.pubfacts.com/detail/12686684" target="_blank" title="" class="tw socialShare" id="tw-a-12686684"><i class="icon-twitter"></i></a> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https://www.pubfacts.com/detail/12686684&title=A+patient+with+sudden+abdominal+pain+10+years+after+successful+renal+transplantation.&summary=Article+Summary+on+PubFacts.com" target="_blank" title="" class="in socialShare" id="in-a-12686684"><i class="icon-linkedin"></i></a> </div></div> </div> </div> <div class="row" > <div class="col-md-12" style="text-align:center;" ><script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script> <!-- Display - Horizontal - Author – Responsive --> <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-8540656545989349" data-ad-slot="2916381101" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> </div> </div> </div> <div class="container" > <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script> <!-- Display - Horizontal - Author – Bottom --> <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-8540656545989349" data-ad-slot="2481266838" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <footer class="bootom-footer"> <div class="end-bottom-info clearfix"> <div class="wrapper"> <div class="bottom-logo fl"> <a href="https://www.pubfacts.com/"> <img src="https://www.pubfacts.com/images/logo.png" alt=""> </a> </div> <span class="copyright-text">© 2021 PubFacts. </span> <ul class="privacylist-link fr"> <li><a href="https://www.pubfacts.com/about">About PubFacts</a></li> <li><a href="https://www.pubfacts.com/privacypolicy">Privacy Policy</a></li> <li><a href="https://www.pubfacts.com/sitemap">Sitemap</a></li> </ul> </div> </div> </footer> <a href="javascript:void(0);" id="ac-gn-curtain"></a> <!-- <form method="post" action="https://www.pubfacts.com/home/search" > --> <script type='text/javascript'> // when the DOM is ready $(function () { $('#topSearchKeyword').keypress(function (e) { if (e.which == 13) { var topSearchInput = $('#topSearchKeyword').val(); $('#searchBlockKeyword').val(topSearchInput); $('#searchBlockForm').submit(); return false; //<---- Add this line } }); $(".clickTrack").click(function(e) { var _this = $(this); var ref = $(this).data('ref'); var arr_ref = ref.split("-"); var clickType=arr_ref[0]; var clickID=arr_ref[1]; var clickIsAdvertiser=arr_ref[2]; //alert(clickType); //alert(clickID); $.ajax({ url: 'https://www.pubfacts.com/ajax/StoreClick', type: 'GET', data: {id:clickID,type:clickType,isAdvertiser:clickIsAdvertiser}, success: function(dataRet) { // alert(dataRet); return true; } }); }); }); </script> <script type="text/javascript" src="https://www.pubfacts.com/js/bootstrap.js"></script> <script type="text/javascript" src="https://www.pubfacts.com/js/jquery.nicescroll.min.js"></script> <script type="text/javascript" src="https://www.pubfacts.com/js/jPushMenu.js"></script> <script type="text/javascript" src="https://www.pubfacts.com/js/main.js?ver=1.2"></script> <script type="text/javascript" src="https://www.pubfacts.com/js/main_addons.js"></script> <script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"7c9985c3c7","applicationID":"27826479","transactionName":"NFNbMEtRXhJVV0NcDQ0ZeAdNWV8PG3VCQQoMRBYNV1RVGQ==","queueTime":0,"applicationTime":1170,"atts":"GBRYRgNLTRw=","errorBeacon":"bam.nr-data.net","agent":""}</script></body> </html>